Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYHX2011 vs Nab-Paclitaxel in First-Line Squamous Non-Small Cell Lung Cancer
NCT07662811Phase 3Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Jun 2026
- Primary completion
- Dec 2027
01
Overview
Phase 3, randomised, open-label trial of SYHX-2011 and PBI-1308 in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai Chest Hospital. Primary endpoints: Objective Response Rate at 3 years and Progression Free Survival at 3 years. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
SYHX-2011PBI-1308
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07662811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07662811.